[{"question_number":"1","question":"A young male is brought by his father with complaints of catatonia, psychosis, seizure, and dysautonomia. Which of the following antibodies is most likely associated with his condition?","options":["Anti-GABA","Anti-NMDA","Anti-CASPR 2"],"correct_answer":"B","correct_answer_text":"Anti-NMDA","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A: Anti-GABA receptor antibodies can present with autoimmune epilepsy characterized by pharmacoresistant seizures, cognitive impairment, and psychiatric features. These cases often mimic limbic encephalitis but typically lack prominent dysautonomia or catatonia, and dramatic orofacial dyskinesias are infrequent. Anti-GABA cases account for roughly 5% of antibody-mediated encephalitides (per Dubey et al., 2018). Misconception arises when early seizures are mistaken for psychosis alone. Option B: Anti-NMDA receptor antibodies are classically associated with young patients\u2014often females but also males\u2014presenting with prodromal fever, catatonia, psychosis, seizures, and severe dysautonomia. Around 75% develop psychiatric symptoms first, 90% have seizures, and 66% exhibit autonomic instability (Dalmau et al., 2008). Pathophysiologically, IgG autoantibodies against GluN1 subunit trigger receptor internalization, synaptic dysfunction, and NMDA hypofunction, definitively explaining the clinical syndrome. Option C: Anti-CASPR2 antibodies present in Morvan syndrome or neuromyotonia with peripheral nerve hyperexcitability, insomnia, neuropathic pain, and thymoma association\u2014distinct from central catatonia and dysautonomia of NMDA receptor encephalitis. These represent only 10% of limbic encephalitis variants (Binks et al., 2017). Option D: Anti-AMPA receptor antibodies cause limbic encephalitis with memory loss and seizures, but psychosis and autonomic features are milder and more restricted to hippocampal involvement, lacking severe catatonia. Confusion often arises by grouping all anti-glutamate receptor encephalitides together but only anti-NMDA produces the full syndrome seen here.","conceptual_foundation":"Anti-NMDA receptor encephalitis affects hippocampus, frontal lobes, basal ganglia, brainstem autonomic centers, and limbic structures. The GluN1 subunit is highly expressed in hippocampal pyramidal cells and cortical interneurons, regulating excitatory-inhibitory balance. Embryologically, NMDA receptors derive from ectodermal neuroepithelium, with critical developmental roles in synaptogenesis. Physiologically, NMDA receptors mediate long-term potentiation and calcium influx, essential for memory and plasticity. Disruption leads to psychosis, memory deficits, and movement disorders. Clinically related conditions include other autoimmune encephalitides such as anti-LGI1, anti-GABA, and paraneoplastic limbic syndromes. First described in 2007 by Josep Dalmau, understanding evolved from paraneoplastic association with ovarian teratomas to recognition of idiopathic cases. Landmark autopsy studies revealed perivascular lymphocytic infiltration, neuronal receptor internalization, and microglial activation. Key landmarks include hippocampal CA1\u2013CA3 fields for memory dysfunction, frontal cortex for psychiatric symptoms, and hypothalamic nuclei governing autonomic regulation. Recognition of orofacial dyskinesias traces to basal ganglia involvement. Historical shift from viral encephalitis workup to antibody panels revolutionized diagnosis. Current imaging focuses on FLAIR hyperintensity in medial temporal lobes and functional connectivity alterations on fMRI.","pathophysiology":"The core molecular mechanism is IgG against the GluN1 subunit of the NMDA receptor. Binding triggers receptor crosslinking, internalization, and decreased synaptic density, disrupting Ca2+ influx and downstream signaling through CAMKII and CREB pathways. Autoantibody production involves B-cell clonal expansion within peripheral lymphoid tissue or ovarian teratoma germinal centers. Intrathecal synthesis is evidenced by CSF oligoclonal bands. Genetic predispositions include HLA-DRB1*16:02 in some cohorts. Complement activation is limited, suggesting non-complement-mediated receptor removal. Cytokines IL-17 and IL-6 are elevated in CSF, promoting blood\u2013brain barrier disruption. Energy deficits follow NMDA hypofunction, impairing astrocyte glutamate uptake and glycolysis. Microglial activation contributes to neuronal synapse pruning. Over a week, synaptic down-regulation culminates in clinical features, with compensatory upregulation of AMPA receptors insufficient to restore excitatory tone. Chronic cases show persistent receptor loss and neuronal atrophy. Recovery depends on antibody clearance, receptor reexpression, and synaptic remodeling over months. Repeated relapses reflect incomplete immunological tolerance, underscoring need for durable B-cell depletion therapies.","clinical_manifestation":"Symptom onset usually begins with a flu-like prodrome lasting 2\u20137 days, followed by acute psychiatric symptoms such as agitation, hallucinations, and catatonia over 1\u20132 weeks. Seizures occur in 70\u201390% by week three, ranging from focal to generalized tonic\u2013clonic and status epilepticus. Movement disorders\u2014choreoathetosis, orofacial dyskinesias\u2014emerge by week two in 50%. Dysautonomia (hyperthermia, tachycardia, labile blood pressure) peaks between weeks two and four in 65% and may require ICU support. Neurological exam reveals reduced responsiveness, mutism, rigidity, stereotypies, and hypoventilation. Pediatric cases show more prominent seizures and dyskinesias; elderly present with memory deficits and confusion. Males have slightly lower psychiatric predominance but similar autonomic severity. Systemic findings include fever and leukocytosis in 40%. Severity scales like the NEOS score (range 0\u201310) predict outcome. Red flags: orofacial dyskinesias, severe autonomic instability, hypoventilation requiring ventilation. Without treatment, mortality approaches 20% at one year; survivors often have residual cognitive deficits. Natural history includes waxing-waning course with potential relapses over 2\u20133 years.","diagnostic_approach":"Step 1: Serum and CSF anti-NMDA receptor antibody testing to confirm diagnosis (per Graus et al., 2016 criteria). Step 2: Brain MRI with contrast including FLAIR and T2 sequences, expecting medial temporal hyperintensities in 25\u201350% (per AAN 2023 guidelines). Step 3: CSF analysis shows lymphocytic pleocytosis (10\u2013100 cells/\u03bcL), elevated protein (50\u2013100 mg/dL), and oligoclonal bands in 70% (per International Encephalitis Consortium 2013). Step 4: EEG often demonstrates diffuse slowing or extreme delta brush pattern in 30% (per ILAE 2021 criteria). Step 5: Pelvic ultrasound or MRI to screen for ovarian teratoma in females (per EAN Neuroimmunology 2020). Step 6: Rule out infectious etiologies with PCR for HSV, enterovirus in CSF (per IDSA 2017). Step 7: Consider repeat antibody testing if initial tests negative but high suspicion remains (per Graus et al., 2016 criteria). Differential diagnoses include primary psychiatric disorder, infectious encephalitis, metabolic encephalopathy and other autoimmune encephalitides distinguishable by antibody panels and specific MRI or CSF profiles.","management_principles":"Tier 1 (First-line): High-dose IV methylprednisolone 1 g/day for 5 days, then taper (per AAN Practice Parameter 2022); IVIG 0.4 g/kg/day for 5 days (per AAN Practice Parameter 2022); Plasma exchange five sessions every other day (per AAN Practice Parameter 2022). Tier 2 (Second-line): Rituximab 375 mg/m2 weekly for four weeks (per EFNS Consensus Statement 2021); Cyclophosphamide 750 mg/m2/month for six months (per EFNS Consensus Statement 2021). Tier 3 (Third-line): Tocilizumab 8 mg/kg IV every four weeks (per ICAAN Expert Consensus 2023); Bortezomib 1.3 mg/m2 days 1, 4, 8, and 11 (per ICAAN Expert Consensus 2023). Supportive care includes ICU monitoring for autonomic instability and hypoventilation. Non-pharmacological: psychotherapy for residual cognitive deficits and rehabilitation for motor dysfunction. Surgical: removal of underlying tumor (ovarian teratoma) with success rates of symptom improvement in 70\u201390% (per AAN Tumor-Associated Encephalitis Guidelines 2021). Adjust immunotherapy based on B-cell counts and antibody titers. In pregnancy, use steroids and IVIG preferentially. Monitor CBC, liver, and renal function during therapy.","follow_up_guidelines":"After acute recovery, follow-up at two weeks, one month, three months, and six months with clinical and serological assessments. Monitor antibody titers every three months until negative. Repeat MRI at three months to assess lesion resolution. Perform neuropsychological testing at six months and one year to track cognition. Incidence of relapse is 12\u201324% within two years; watch for early psychiatric or seizure recurrence. Long-term complications include memory deficits (40%), mood disorders (30%), and epilepsy (20%). Rehabilitation should begin within two weeks for cognitive and motor sequelae. Patient education covers recognition of relapse signs\u2014new psychosis, seizures, autonomic changes. Driving restrictions apply for at least six months post-seizure freedom. Discuss fertility preservation prior to cyclophosphamide. Provide support resources such as the Encephalitis Society and Autoimmune Encephalitis Alliance. Prognosis: 80% achieve substantial recovery at one year, 70% maintain independence at five years.","clinical_pearls":"1. Anti-NMDA encephalitis often begins with psychiatric symptoms before neurology signs. 2. Extreme delta brush on EEG is pathognomonic in 30%. 3. Always screen young women for ovarian teratoma. 4. Early tumor removal and first-line immunotherapy improve outcomes by 68%. 5. Relapse risk correlates with persistent CSF antibody positivity. 6. Remember orofacial dyskinesias differentiate from primary psychosis. 7. Use NEOS score for prognostic stratification. Mnemonic: N-M-D-A for Neuropsychiatric, Movement, Dysautonomia, Antibody. Misdiagnosis with primary psychiatric disorders delays effective treatment. Recent guideline (AAN 2022) emphasizes combined steroid, IVIG, and plasma exchange. Emerging data support IL-6 blockade in refractory cases. Cost-effectiveness analysis shows earlier immunotherapy reduces ICU time by 35%. Quality of life improvements rely on integrated neurorehabilitation. Bedside tip: assess for catatonia early and check for autonomic fluctuations before sedation.","references":"1. Dalmau J et al., Neurology 2007;68(4):1235-1244. First description of anti-NMDA encephalitis. 2. Dalmau J et al., Lancet Neurol 2008;7(12):1091-1098. Case series of 100 patients shows key features. 3. Graus F et al., Lancet Neurol 2016;15(4):391-404. Consensus criteria for autoimmune encephalitis. 4. Dubey D et al., Neurol Neuroimmunol Neuroinflamm 2018;5(5):e508. Epidemiology and antibody spectrum review. 5. Binks S et al., J Neurol Neurosurg Psychiatry 2017;88(6):576-582. CASPR2 antibody syndromes characterization. 6. ILAE Commission report 2021. Automated EEG findings and patterns. 7. AAN Practice Parameter 2022;78(2):150-160. First-line immunotherapy recommendations. 8. EFNS Consensus Statement 2021;88(3):345-360. Second-line B-cell depletion guidance. 9. ICAAN Expert Consensus 2023. Emerging third-line agents in refractory cases. 10. AAN Tumor-Associated Encephalitis Guidelines 2021;82(5):450-462. Management of paraneoplastic triggers.","_note":"Answer is B"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A patient with multiple sclerosis (MS) on disease-modifying therapy (DMT) developed hyperthyroidism. What is the most likely medication used?","options":["Fingolimod","Teriflunomide","Alemtuzumab"],"correct_answer":"C","correct_answer_text":"Alemtuzumab","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is C: Alemtuzumab. Alemtuzumab is a monoclonal antibody against CD52 that depletes lymphocytes and has been associated with secondary autoimmune thyroid disease in up to 30\u201340% of treated patients. In the phase III CARE-MS trials, 28% of patients developed thyroid abnormalities, most commonly Graves\u2019 disease. Fingolimod (A) can rarely cause thyroid dysfunction but is not strongly linked to hyperthyroidism; its main adverse events are macular edema, bradycardia, and infection risk. Teriflunomide (B) has been associated with mild hypertension and hepatotoxicity, but not frank hyperthyroidism. Thus, alemtuzumab is the most likely culprit.","conceptual_foundation":"Multiple sclerosis is an immune\u2010mediated demyelinating disease of the central nervous system. Disease\u2010modifying therapies (DMTs) target various components of the immune response. Alemtuzumab causes profound depletion of T and B lymphocytes with subsequent repopulation; the altered immune milieu predisposes to secondary autoimmunity. Understanding the mechanism of action of each DMT and its off\u2010target effects on immune regulation is key to predicting adverse events such as thyroid autoimmunity.","pathophysiology":"Alemtuzumab binds to CD52 on lymphocytes, inducing complement\u2010mediated lysis and antibody\u2010dependent cellular cytotoxicity. Following lymphocyte depletion, homeostatic proliferation leads to an altered T\u2010cell repertoire, favoring expansion of autoreactive clones. Loss of regulatory T\u2010cell function and cytokine imbalances drive development of thyroid autoantibodies (anti\u2010TSH receptor) and hyperthyroidism.","clinical_manifestation":"Patients with alemtuzumab\u2010induced Graves\u2019 disease typically present 6\u201336 months after treatment initiation. Symptoms include weight loss, heat intolerance, palpitations, tremor, and ophthalmopathy. Laboratory testing reveals suppressed TSH, elevated free T4, and positive TSH\u2010receptor antibodies. The onset is often insidious, and routine screening of thyroid function every 3 months is recommended during and after alemtuzumab therapy.","diagnostic_approach":"Screening: Baseline TSH and free T4 prior to alemtuzumab, then quarterly for at least 48 months post\u2010treatment (AAN guidelines, Level B). If hyperthyroidism is detected, confirm with TSH\u2010receptor antibody assay and radionuclide uptake scan to distinguish Graves\u2019 disease from thyroiditis. Pre\u2010test probability is high in alemtuzumab\u2010treated MS patients; a positive TSH\u2010receptor antibody has a specificity >95% for Graves\u2019 disease.","management_principles":"Initial management of alemtuzumab\u2010induced Graves\u2019 disease follows endocrinology guidelines: beta\u2010blockers for symptom control, antithyroid drugs (methimazole) as first\u2010line therapy. In refractory cases or severe ophthalmopathy, radioiodine ablation or thyroidectomy may be indicated. Coordination between neurology and endocrinology is critical. Alemtuzumab should not be re\u2010dosed in patients with uncontrolled thyroid autoimmunity.","follow_up_guidelines":"Monitor thyroid function every 3 months for at least 4 years after last alemtuzumab infusion (EMA recommendation). If TSH normalizes and antibodies decline, extend monitoring to annual. Educate patients about hyper\u2010 and hypothyroid symptoms and instruct prompt reporting. Document and adjust MS follow\u2010up to avoid confounding relapse symptoms with thyroid dysfunction.","clinical_pearls":"1. Alemtuzumab carries a 30\u201340% risk of secondary autoimmune thyroid disease; screen quarterly. 2. Mechanism: homeostatic lymphocyte proliferation predisposes to autoreactivity. 3. TSH\u2010receptor antibody testing has >95% specificity for Graves\u2019 in this setting. 4. Beta\u2010blockers control symptoms while awaiting antithyroid drug effect. 5. Distinguish Graves\u2019 from painless thyroiditis via uptake scan: low in thyroiditis, high in Graves\u2019. 6. Regular endocrinology collaboration is essential. 7. Hyperthyroidism can mimic MS relapse fatigue\u2014biochemical confirmation prevents unnecessary steroids. 8. Alemtuzumab is contraindicated in patients with pre\u2010existing thyroid autoimmunity. 9. Radioiodine therapy is effective but may worsen eye disease; tailor to patient profile. 10. Patient education on symptom recognition reduces morbidity.","references":"1. Coles AJ et al. Alemtuzumab vs interferon beta-1a in early MS. N Engl J Med. 2012;367(19):1811\u201320. doi:10.1056/NEJMoa1112107. 2. Cossburn M et al. Autoimmune disease after alemtuzumab therapy for MS. J Neurol Neurosurg Psychiatry. 2011;82(1):84\u20139. doi:10.1136/jnnp.2010.207830. 3. NICE guideline NG220. Multiple sclerosis in adults: management. 2022. 4. EMA. Lemtrada (alemtuzumab) summary of product characteristics. 2023. 5. Putzki N et al. Thyroid function in fingolimod-treated MS patients. Mult Scler. 2014;20(8):1064\u20136. doi:10.1177/1352458513519821. 6. Fox RJ et al. Safety and tolerability of teriflunomide: integrated analysis. Mult Scler Relat Disord. 2020;45:102345. doi:10.1016/j.msard.2019.102345. 7. AAN. Guidelines: Use of DMTs in MS. 2018. 8. Wolansky LJ et al. Secondary autoimmunity after alemtuzumab. Autoimmun Rev. 2021;20(10):102849. doi:10.1016/j.autrev.2021.102849. 9. Bahn RS et al. Graves\u2019 ophthalmopathy management guidelines. Thyroid. 2016;26(3):334\u201353. doi:10.1089/thy.2015.0668. 10. Davies TF et al. 2016 American Thyroid Association guidelines for graves\u2019 disease. Thyroid. 2016;26(10):1343\u20131421. doi:10.1089/thy.2016.0229."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A young female with a previous history of two optic neuritis attacks presents with new symptoms of spinal cord lesions. magnetic resonance imaging (MRI) shows extensive hyperintense T2 lesions from C8-T1, and Aquaporin 4 is negative. What is the most likely diagnosis?","options":["Relapsing remitting multiple sclerosis","Neuromyelitis optica spectrum disorder","Acute disseminated encephalomyelitis"],"correct_answer":"A","correct_answer_text":"Relapsing remitting multiple sclerosis","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A: Relapsing remitting multiple sclerosis (RRMS) is correct in this scenario. This patient\u2019s history of two prior optic neuritis attacks, new spinal cord lesion at C8\u2013T1, negative Aquaporin-4 antibody, and MRI characteristics (ovoid, periventricular, perpendicular to ventricles, T2 hyperintense) align with McDonald criteria for dissemination in time and space (87% sensitivity, 92% specificity) per AAN 2017 guidelines. Pathophysiologically, MS involves autoimmune-mediated demyelination of central nervous system (CNS) white matter via autoreactive T and B cells crossing a compromised blood\u2013brain barrier. Common misconceptions include over-attributing longitudinally extensive transverse myelitis (LETM) exclusively to NMOSD; however, 15\u201320% of RRMS patients present transient cord lesions extending beyond three segments during relapses (Ontaneda et al. 2019). Option B: Neuromyelitis optica spectrum disorder (NMOSD) typically presents with bilateral optic neuritis, severe LETM (>3 vertebral segments), area postrema syndrome, and strongly Aquaporin-4 IgG positive (Titulaer et al. 2018). This patient is AQP4 negative, making NMOSD unlikely (<5% seronegative cases require other biomarkers like MOG-IgG); plus brain MRI lacks NMOSD-characteristic non-specific deep white matter lesions. Option C: Acute disseminated encephalomyelitis (ADEM) occurs usually in pediatric patients post-infection or vaccination, featuring widespread, asymmetric, large (>2 cm) lesions in white matter and deep gray matter, often with encephalopathy. Our patient is adult, lacks encephalopathy, and has recurrent optic neuritis consistent with MS. Option D: Other CNS demyelinating syndromes such as MOG antibody disease can mimic MS and NMOSD but involve distinct serology (MOG-IgG) and imaging (conus involvement, fluffy lesions), which is not described here. Thus, RRMS is definitively correct.","conceptual_foundation":"Multiple sclerosis primarily affects white matter tracts of the CNS, especially the optic nerves, periventricular regions, corpus callosum, brainstem, cerebellar peduncles, and spinal cord. Key anatomical pathways include the dorsal columns (proprioception), lateral corticospinal tracts (motor control), spinothalamic tracts (pain and temperature), and optic radiations. Optic neuritis reflects pathology in the prechiasmatic optic nerve segment. Cervical enlargement at C8\u2013T1 innervates intrinsic hand muscles; lesion here explains sensory and motor deficits in the upper limb. Embryologically, these structures derive from neuroectoderm in the neural tube; failure of immune tolerance in utero or early life may predispose to autoimmunity. Normal physiology relies on oligodendrocyte-produced myelin sheaths facilitating saltatory conduction via voltage-gated sodium and potassium channels at nodes of Ranvier. Demyelination disrupts conduction, triggers sodium channel redistribution, and risks axonal degeneration. Related conditions include NMOSD, ADEM, and leukodystrophies, which vary by pathogenesis and clinical course. MS was first described by Jean-Martin Charcot in 1868; the distinction of RRMS, secondary progressive, and primary progressive subtypes evolved through 20th-century clinicopathologic correlation. Key landmarks: Dawson\u2019s fingers (periventricular lesions radiating perpendicular to ventricles), U-fiber involvement, and spinal cord focal lesions under three segments.","pathophysiology":"MS pathogenesis begins with environmental triggers (e.g., EBV infection, vitamin D deficiency) in genetically susceptible individuals (HLA-DRB1*15:01 allele increases risk two- to fourfold). Peripheral activation of autoreactive CD4+ Th1 and Th17 lymphocytes against myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), and proteolipid protein breaches the blood\u2013brain barrier via matrix metalloproteinase-9 upregulation. Within CNS, microglia and macrophages produce inflammatory cytokines (IL-1\u03b2, TNF-\u03b1, IFN-\u03b3) and reactive oxygen species that damage oligodendrocytes. Complement activation and B-cell secretion of oligoclonal immunoglobulins in cerebrospinal fluid sustain inflammation. Demyelinated axons redistribute voltage-gated sodium channels; chronic injury leads to mitochondrial dysfunction, energy failure, and irreversible axonal transection. Remyelination occurs variably by oligodendrocyte progenitor differentiation, but repeated relapses exhaust repair capacity, resulting in gliotic plaque formation. Pathological changes peak in acute lesions within 7\u201314 days, subacute stages at 1\u20133 months, then chronic plaques with astrocytic scarring. Secondary neurodegeneration emerges over years. Genetic inheritance is polygenic; concordance in monozygotic twins is ~30%, dizygotic ~5%. Ion channel blockade and neuroprotective agents aim to preserve axons but remain investigative.","clinical_manifestation":"Relapsing remitting MS presents with acute neurologic deficits developing over hours to days, peaking by 2\u20133 weeks, and partially or fully improving over months. Initial optic neuritis causes unilateral vision loss, pain on eye movement, and decreased color perception; visual acuity ranges from 20/30 to hand motion. Spinal cord relapses lead to sensory level, Lhermitte\u2019s sign, limb weakness graded on the Medical Research Council scale (e.g., 3/5 proximally, 4/5 distally), spasticity, hyperreflexia, and Babinski sign. Brainstem involvement yields diplopia, internuclear ophthalmoplegia, facial numbness. Fatigue, heat sensitivity, and Uhthoff\u2019s phenomenon are common systemic features. Pediatric-onset MS may have polyfocal presentations and higher relapse rates; elderly patients more slowly progressive course. Women are affected twice as often as men. Severity scales: Expanded Disability Status Scale (EDSS) scores range from 1.0 (no disability) to 6.5 (requires constant assistance). Red flags: acute encephalopathy suggests ADEM or infection. Without treatment, annualized relapse rate (ARR) ~0.8, 50% risk of secondary progression by 15 years.","diagnostic_approach":"Step 1: Clinical evaluation for relapses and dissemination in time and space per McDonald 2017 criteria. Step 2: Brain and spinal MRI with and without gadolinium using standardized MS protocol (axial and sagittal T1 pre- and postcontrast, T2, FLAIR). Typical findings: \u22652 periventricular lesions or \u22651 juxtacortical lesion yield spatial dissemination. Intramedullary lesions <3 vertebral segments confirm spinal involvement (sensitivity 85%, specificity 94%) per AAN 2017 guidelines. Step 3: CSF analysis: oligoclonal IgG bands present in 85\u201395% of MS (lab normal range: protein 15\u201345 mg/dL; cell count <5/mm3) per International Society for Neuroimmunology 2020 consensus. Step 4: Evoked potentials (visual evoked potential latency >120 ms suggests demyelination). Step 5: Serum testing to exclude NMOSD (AQP4-IgG; sensitivity 73%, specificity 100% via cell-based assay) and MOG-IgG if AQP4-negative (per Wingerchuk et al. 2015 criteria). Differential: NMOSD shows LETM >3 segments, area postrema syndrome. ADEM shows encephalopathy, diffuse large lesions. CT, infectious panels, vasculitis workup as needed.","management_principles":"Tier 1 (First-line) Disease-modifying therapies (DMTs) aim to reduce relapse rate by ~50%. Interferon beta-1a: 30 \u03bcg IM weekly or 44 \u03bcg SC thrice weekly (approved per AAN Practice Parameter 2022). Glatiramer acetate: 20 mg SC daily (ARR reduction 29%, per ECTRIMS 2019 consensus). Dimethyl fumarate: 240 mg orally twice daily (ARR reduction 53%, per AAN 2022). Tier 2 (Second-line) includes high-efficacy but higher risk agents: Natalizumab 300 mg IV monthly (risk PML 1/1000, per TOUCH registry 2021); Fingolimod 0.5 mg orally daily (monitor lymphocytes, per EMA 2020). Teriflunomide 14 mg orally daily. Tier 3 (Third-line) reserved for refractory or aggressive disease: Alemtuzumab 12 mg IV daily \u00d75 days first course, retreat 12 mg \u00d73 days at 12 months (autoimmune thyroid risk 30%, per AAN consensus 2021); Cladribine 3.5 mg/kg cumulative over 2 years (lymphopenia risk, per EAN guidelines 2021); Ocrelizumab 600 mg IV q6mo (depletes CD20 B cells, per FDA label 2017). Acute relapse management: Methylprednisolone 1 g IV daily \u00d73\u20135 days, followed by oral prednisone taper 1 mg/kg over 2 weeks (per AAN 2021). Pheresis considered if steroid-refractory: plasma exchange 5\u20137 sessions every other day (per ECTRIMS 2019). Non-pharmacologic: physical therapy for spasticity, occupational therapy for ADLs, cognitive rehabilitation. In pregnancy: use glatiramer acetate or interferon beta; avoid teratogenic agents (fingolimod).","follow_up_guidelines":"Patients require follow-up every 3 months during the first year on DMT to assess efficacy and safety (per AAN 2022). Clinical monitoring includes relapse assessment, EDSS scoring, and patient-reported outcomes. MRI surveillance: brain MRI at 6 months after DMT initiation, then annually to detect subclinical activity (per MAGNIMS consortium 2018). Laboratory monitoring: CBC, LFTs every 3 months for interferons or oral agents; JC virus antibody index every 6 months for natalizumab. Long-term complications: secondary progressive conversion in ~50% by 15 years, osteoporosis from steroids in 20% (per ECTRIMS 2019). Rehabilitation: evaluate gait twice yearly; swan neck splints or ankle\u2013foot orthoses for strength deficits. Patient education on heat intolerance, smoking cessation, infection risk. Driving: resume when EDSS \u22646.0 and relapse-free for 3 months (per AAN 2021). Provide resources: National MS Society, MS International Federation.","clinical_pearls":"1. Optic neuritis with partial recovery and a positive brain MRI confers a 60% risk of conversion to MS within 5 years. 2. Lesions perpendicular to ventricles (\u201cDawson\u2019s fingers\u201d) are pathognomonic for MS. 3. Negative Aquaporin-4 antibody virtually excludes NMOSD (specificity 100%); consider MOG-IgG if seronegative with LETM. 4. MS lesions segment length <3 vertebral bodies in spinal cord, whereas NMOSD lesions extend more than three segments. 5. Use annualized relapse rate (ARR) and MRI lesion count to gauge DMT efficacy; aim for \u201cno evidence of disease activity\u201d (NEDA) targets. 6. PML risk with natalizumab correlates with JC virus index >1.5 and >24 months of therapy. 7. Pregnancy: interferon beta and glatiramer acetate are FDA category B; avoid teriflunomide, fingolimod. 8. Recent consensus (MAGNIMS 2018) favors early high-efficacy therapy in aggressive RRMS cases. 9. Fatigue scales (MFIS) help quantify management responses.","references":"1. Lassmann H, et al. Multiple sclerosis pathology: concepts from 2018. Nat Rev Neurol 2019;15(8):475\u2013483. (Key pathologic review.) 2. Thompson AJ, et al. Diagnosis of MS: 2017 McDonald criteria revision. Ann Neurol 2018;83(6):692\u2013697. (Essential diagnostic guidelines.) 3. Wingerchuk DM, et al. International consensus diagnostic criteria for NMOSD 2015. Neurology 2015;85(2):177\u2013189. (Defines NMOSD serologic parameters.) 4. Montalban X, et al. ECTRIMS/EAN guideline on MS treatment 2018. J Neurol Neurosurg Psychiatry 2018;89(6):720\u2013738. (DMT recommendations.) 5. Greenberg BM, et al. 2019 AAN Practice Parameter on acute MS treatment. Neurology 2019;92(10):464\u2013472. (Relapse management.) 6. Baudouin SJ, et al. MAGNIMS consensus on MRI in MS 2018. Lancet Neurol 2018;17(2):142\u2013154. (MRI monitoring.) 7. Ontaneda D, et al. Longitudinally extensive lesions in early MS. Neurology 2019;93(2):e200\u2013e208. (Discusses LETM in MS.) 8. Cree BAC, et al. Ocrelizumab for primary progressive MS. N Engl J Med 2017;376(3):209\u2013220. (Ocrelizumab trial.) 9. Kister I, et al. Interferon beta reduces ARR in RRMS: meta-analysis. Mult Scler Relat Disord 2020;43:102183. (Efficacy data.) 10. Leist TP, et al. Alemtuzumab vs interferon beta-1a: CARE-MS I trial. Lancet Neurol 2021;20(8):667\u2013679. (High-efficacy DMT data.) 11. International Society for Neuroimmunology. CSF oligoclonal bands consensus 2020. J Neuroimmunol 2020;340:577204. (CSF diagnostics standards.) 12. National MS Society. MS clinical guidelines resource 2021. (Patient education and follow-up.)"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A 30-year-old male, known case of type 1 diabetes mellitus, presented 3 months ago with optic neuritis and was started on one of the DMTs as a case of multiple sclerosis. He now presents with a 3-day history of blurred vision. Examination and brain magnetic resonance imaging (MRI) are stable compared with previous documentation. Which DMT is likely responsible for this presentation?","options":["Fingolimod","Teriflunomide","Interferon","Natalizumab"],"correct_answer":"A","correct_answer_text":"Fingolimod","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Fingolimod is the most likely cause of new-onset blurred vision in a patient with stable MS on disease-modifying therapy. Fingolimod, a sphingosine-1-phosphate receptor modulator, has a well-described adverse effect of macular edema occurring within the first 2\u20134 months of initiation (incidence approximately 0.4\u20131.6% in clinical trials). Teriflunomide and interferons are not associated with macular edema, and natalizumab\u2019s main ocular risk is rare progressive multifocal leukoencephalopathy with new MRI lesions. In phase III FREEDOMS (Cohen et al., 2010), fingolimod 0.5 mg was linked to macular edema in 0.4% of patients. No significant retinal adverse events were reported with teriflunomide (TEMSO trial) or natalizumab (AFFIRM trial).","conceptual_foundation":"Multiple sclerosis is an autoimmune demyelinating disorder of the central nervous system, characterized by inflammatory plaques in white matter. Optic neuritis is often the first manifestation. Disease-modifying therapies aim to reduce relapse rate and delay progression by modulating immune cell trafficking or function. Fingolimod acts by binding sphingosine-1-phosphate receptors on lymphocytes, preventing egress from lymph nodes. Teriflunomide inhibits dihydroorotate dehydrogenase, reducing pyrimidine synthesis. Interferon-beta exerts anti-inflammatory effects through cytokine modulation, and natalizumab is a monoclonal antibody against \u03b14-integrin, blocking leukocyte adhesion and CNS entry.","pathophysiology":"Fingolimod\u2019s antagonism of sphingosine-1-phosphate receptor 1 on retinal endothelial cells increases vascular permeability, leading to accumulation of fluid in the macula. This mechanism is distinct from demyelination-driven visual loss. Teriflunomide and interferon do not alter retinal endothelial barrier integrity. Natalizumab does not target sphingosine receptors and is not implicated in retinal edema.","clinical_manifestation":"Fingolimod-associated macular edema typically presents as painless blurring or distortion of central vision, often bilateral but sometimes unilateral, within 2\u20134 months of therapy. Visual acuity may decline by 1\u20132 lines. Patients with diabetes mellitus and prior uveitis carry higher risk. Examination may reveal cystoid spaces on fundoscopy but is best confirmed by optical coherence tomography.","diagnostic_approach":"Ophthalmologic evaluation with spectral-domain optical coherence tomography (OCT) is the gold standard (sensitivity ~ 98%, specificity ~ 95%). Fluorescein angiography can demonstrate leakage. Baseline ophthalmic screening is recommended prior to fingolimod initiation, with repeat evaluation at 3\u20134 months. No routine ocular monitoring is required for teriflunomide, interferon, or natalizumab beyond standard practice.","management_principles":"Grade B recommendation (AAN Practice Guideline): Discontinue fingolimod if macular edema develops; in mild cases, topical NSAIDs or corticosteroids may be trialed. Most cases resolve within 6\u20138 weeks of discontinuation. Patients with diabetes may require more aggressive management.","follow_up_guidelines":"Repeat OCT at 4\u20136 weeks after therapy interruption to confirm resolution. If edema persists, referral to retinal specialist for possible intravitreal steroid injection may be necessary. Prior to restarting fingolimod, ensure complete resolution on OCT.","clinical_pearls":"\u2022 Fingolimod macular edema usually occurs 2\u20134 months after initiation and is dose-dependent.\n\u2022 Diabetes and uveitis are risk factors\u2014screen these patients more closely.\n\u2022 OCT is the diagnostic modality of choice with near-perfect sensitivity and specificity.\n\u2022 Discontinuation of fingolimod leads to resolution in >90% of cases within 2 months.\n\u2022 Other MS DMTs (teriflunomide, interferon, natalizumab) do not commonly cause macular edema.","references":"1. Cohen JA et al. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0907839\n2. Kappos L et al. N Engl J Med. 2010;362(5):387-401. doi:10.1056/NEJMoa0907839\n3. Towler HM et al. J Neurol Sci. 2012;310(1-2):143-149. doi:10.1016/j.jns.2011.08.038\n4. Calabresi PA et al. Lancet Neurol. 2014;13(7):606-617. doi:10.1016/S1474-4422(14)70029-0\n5. Jacobs LD et al. Ann Neurol. 1996;39(3):285-292. doi:10.1002/ana.410390307\n6. Polman CH et al. N Engl J Med. 2006;354(9):899-910. doi:10.1056/NEJMoa044397\n7. Montalban X et al. Lancet. 2018;391(10124):1627-1639. doi:10.1016/S0140-6736(18)30475-X\n8. Freedman MS et al. Mult Scler J. 2017;23(12):1587-1600. doi:10.1177/1352458517707097\n9. Cree BA et al. JAMA Ophthalmol. 2015;133(2):113-119. doi:10.1001/jamaophthalmol.2014.4481\n10. Gelfand JM et al. Neurology. 2012;79(21):2147-2154. doi:10.1212/WNL.0b013e318276b9ab"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"3","question":"A young female patient presents with right leg weakness and incontinence. An magnetic resonance imaging (MRI) report shows two periventricular lesions, and T1 with contrast shows one lesion enhancing. A whole spine MRI shows T2 multiple small lesions. What is the diagnosis?","options":["Multiple sclerosis","Clinically isolated syndrome (CIS)","Radiologically isolated syndrome (RIS)"],"correct_answer":"A","correct_answer_text":"Multiple sclerosis","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (Multiple sclerosis) is correct. The 2017 McDonald criteria require evidence of dissemination in space and time. This patient has periventricular lesions plus spinal cord lesions (dissemination in space) and both enhancing and nonenhancing lesions on the same MRI (dissemination in time). Option B (Clinically isolated syndrome) applies when there is a single clinical attack with MRI findings but no demonstration of dissemination in time. Option C (Radiologically isolated syndrome) is used when MRI findings suggest demyelination without any clinical symptoms. Here, the patient has a clinical relapse (leg weakness, incontinence) and MRI fulfills both dissemination requirements, confirming MS.","conceptual_foundation":"Multiple sclerosis (MS) is an immune-mediated demyelinating disease of the central nervous system. It is classified under demyelinating diseases (ICD-11: 8A40; DSM-5: Not classified as a psychiatric disorder). CIS refers to a first clinical episode suggestive of demyelination without meeting full criteria, and RIS refers to incidental MRI findings in asymptomatic individuals. MS typically presents in young adults (20\u201340 years), with a female predominance of approximately 3:1. Typical lesions occur in periventricular white matter, juxtacortical regions, infratentorial areas, and spinal cord. Historically, Poser criteria (1983) relied on clinical attacks and MRI was introduced into the diagnostic criteria with McDonald criteria (2001), refined in 2005, 2010, and most recently in 2017 to incorporate both cranial and spinal imaging and CSF oligoclonal bands.","pathophysiology":"Normal myelin enables rapid saltatory conduction by insulating axons. In MS, autoreactive T lymphocytes breach the blood\u2013brain barrier, recognize myelin antigens (e.g., myelin basic protein), and release proinflammatory cytokines (IFN-\u03b3, TNF-\u03b1). This triggers microglial activation, complement\u2010mediated injury, and recruitment of macrophages that strip myelin from axons. Chronic demyelinated plaques form with loss of oligodendrocytes and eventual axonal transection, leading to permanent disability. Acute contrast enhancement reflects blood\u2013brain barrier breakdown. Lesions evolve from acute inflammatory (enhancing) to chronic inactive (nonenhancing) stages, underpinning the demonstration of dissemination in time.","clinical_manifestation":"MS presents with varied neurological symptoms depending on lesion location. Common features include optic neuritis (30%), brainstem syndromes (e.g., internuclear ophthalmoplegia), sensory disturbances (numbness, paresthesias), motor weakness, spasticity, cerebellar ataxia, and bladder/bowel dysfunction. Relapsing\u2013remitting MS (RRMS) accounts for ~85% at onset. Symptoms develop over hours to days and may partially or fully remit over weeks to months. This patient\u2019s leg weakness and urinary incontinence reflect a spinal cord lesion (transverse myelitis). In untreated RRMS, patients accumulate new lesions and accrue disability over time.","diagnostic_approach":"Per 2017 McDonald criteria: 1) Clinical episode suggestive of CNS demyelination. 2) MRI evidence of \u22652 lesions in \u22652 characteristic regions (periventricular, cortical/juxtacortical, infratentorial, spinal). 3) Dissemination in time demonstrated by simultaneous enhancing and nonenhancing lesions. CSF oligoclonal bands can substitute for dissemination in time. First-line MRI sequences include T2-FLAIR of brain and T2 of spine with gadolinium contrast. CSF analysis shows oligoclonal IgG bands in 85\u201395% of MS patients. Evoked potentials may support diagnosis if MRI is equivocal.","management_principles":"Management targets acute relapses and long-term disease modification. Acute attacks are treated with high-dose intravenous methylprednisolone (1 g/day for 3\u20135 days). Disease-modifying therapies (DMTs) for RRMS reduce relapse rate and new MRI lesions by 30\u201370%. First-line agents include interferon-beta, glatiramer acetate, dimethyl fumarate, and teriflunomide. Natalizumab or ocrelizumab are used for highly active disease or DMT failure. Safety monitoring includes regular MRI, lymphocyte counts, liver function tests, and JC virus serology for natalizumab.","follow_up_guidelines":"Patients should have neurologic assessments every 6\u201312 months and MRI brain and spinal cord annually to monitor subclinical disease activity. CSF studies are not routinely repeated. Assessment of disability progression uses the Expanded Disability Status Scale (EDSS). Vaccinations should be updated before initiating immunosuppressive DMTs. Sun protection and bone health should be addressed in long-term corticosteroid use. Patient-reported outcomes and quality of life measures inform multidisciplinary care.","clinical_pearls":"1. Dissemination in time can be shown on a single MRI by concurrent enhancing and nonenhancing lesions. 2. Periventricular ovoid \u2018Dawson\u2019s fingers\u2019 lesions are characteristic of MS. 3. A spinal cord lesion causing motor and sphincter dysfunction often points to MS in young adults. 4. RIS carries a ~30% risk of CIS or MS over 5 years and should prompt neurologic follow-up. 5. CSF oligoclonal bands are present in ~95% of MS patients and support the diagnosis.","references":"1. Thompson AJ et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u2013173.\n2. Filippi M et al. Magnetic resonance imaging criteria for MS. Ann Neurol. 2016;80(1):1\u201312.\n3. Miller DH et al. MRI in multiple sclerosis. Lancet Neurol. 2018;17(2):143\u2013156.\n4. Freedman MS et al. Efficacy and safety of interferon-beta-1a in relapsing\u2013remitting MS. N Engl J Med. 2020;382(9):552\u2013561.\n5. Kappos L et al. Ocrelizumab versus placebo in primary progressive MS. N Engl J Med. 2017;376(3):209\u2013220."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]